Literature DB >> 19924114

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

Sagnik Bhattacharyya1, Paul D Morrison, Paolo Fusar-Poli, Rocio Martin-Santos, Stefan Borgwardt, Toby Winton-Brown, Chiara Nosarti, Colin M O' Carroll, Marc Seal, Paul Allen, Mitul A Mehta, James M Stone, Nigel Tunstall, Vincent Giampietro, Shitij Kapur, Robin M Murray, Antonio W Zuardi, José A Crippa, Zerrin Atakan, Philip K McGuire.   

Abstract

Delta-9-tetrahydrocannabinol (Delta-9-THC) and Cannabidiol (CBD), the two main ingredients of the Cannabis sativa plant have distinct symptomatic and behavioral effects. We used functional magnetic resonance imaging (fMRI) in healthy volunteers to examine whether Delta-9-THC and CBD had opposite effects on regional brain function. We then assessed whether pretreatment with CBD can prevent the acute psychotic symptoms induced by Delta-9-THC. Fifteen healthy men with minimal earlier exposure to cannabis were scanned while performing a verbal memory task, a response inhibition task, a sensory processing task, and when viewing fearful faces. Subjects were scanned on three occasions, each preceded by oral administration of Delta-9-THC, CBD, or placebo. BOLD responses were measured using fMRI. In a second experiment, six healthy volunteers were administered Delta-9-THC intravenously on two occasions, after placebo or CBD pretreatment to examine whether CBD could block the psychotic symptoms induced by Delta-9-THC. Delta-9-THC and CBD had opposite effects on activation relative to placebo in the striatum during verbal recall, in the hippocampus during the response inhibition task, in the amygdala when subjects viewed fearful faces, in the superior temporal cortex when subjects listened to speech, and in the occipital cortex during visual processing. In the second experiment, pretreatment with CBD prevented the acute induction of psychotic symptoms by Delta-9-tetrahydrocannabinol. Delta-9-THC and CBD can have opposite effects on regional brain function, which may underlie their different symptomatic and behavioral effects, and CBD's ability to block the psychotogenic effects of Delta-9-THC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19924114      PMCID: PMC3055598          DOI: 10.1038/npp.2009.184

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  47 in total

1.  Distinct roles for lateral and medial anterior prefrontal cortex in contextual recollection.

Authors:  Jon S Simons; Sam J Gilbert; Adrian M Owen; Paul C Fletcher; Paul W Burgess
Journal:  J Neurophysiol       Date:  2005-02-23       Impact factor: 2.714

2.  Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol.

Authors:  I G Karniol; E A Carlini
Journal:  Psychopharmacologia       Date:  1973-10-23

3.  Marijuana intoxication common experiences.

Authors:  C T Tart
Journal:  Nature       Date:  1970-05-23       Impact factor: 49.962

4.  Effects of smoking marijuana on brain perfusion and cognition.

Authors:  Daniel S O'Leary; Robert I Block; Julie A Koeppel; Michael Flaum; Susan K Schultz; Nancy C Andreasen; Laura Boles Ponto; G Leonard Watkins; Richard R Hurtig; Richard D Hichwa
Journal:  Neuropsychopharmacology       Date:  2002-06       Impact factor: 7.853

5.  Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.

Authors:  Isabel Lastres-Becker; Francisco Molina-Holgado; José A Ramos; Raphael Mechoulam; Javier Fernández-Ruiz
Journal:  Neurobiol Dis       Date:  2005 Jun-Jul       Impact factor: 5.996

6.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

Review 7.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

8.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

Authors:  A J Hampson; M Grimaldi; J Axelrod; D Wink
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

9.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Authors:  Paolo Fusar-Poli; José A Crippa; Sagnik Bhattacharyya; Stefan J Borgwardt; Paul Allen; Rocio Martin-Santos; Marc Seal; Simon A Surguladze; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip K McGuire
Journal:  Arch Gen Psychiatry       Date:  2009-01

10.  Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.

Authors:  Celia J A Morgan; H Valerie Curran
Journal:  Br J Psychiatry       Date:  2008-04       Impact factor: 9.319

View more
  229 in total

1.  Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users.

Authors:  Joseph P Schacht; Kent E Hutchison; Francesca M Filbey
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect.

Authors:  Christine A Rabinak; Chandra Sekhar Sripada; Mike Angstadt; Harriet de Wit; K Luan Phan
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

Review 3.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

Authors:  Shanna Babalonis; Margaret Haney; Robert J Malcolm; Michelle R Lofwall; Victoria R Votaw; Steven Sparenborg; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-12-14       Impact factor: 4.492

Review 5.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 6.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

7.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 8.  Cannabis Epidemiology: A Selective Review.

Authors:  James C Anthony; Catalina Lopez-Quintero; Omayma Alshaarawy
Journal:  Curr Pharm Des       Date:  2017-01-04       Impact factor: 3.116

9.  Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans.

Authors:  Michael E Ballard; David A Gallo; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2012-12-09       Impact factor: 4.530

Review 10.  The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information.

Authors:  Arun Swaminath; Eric P Berlin; Adam Cheifetz; Ed Hoffenberg; Jami Kinnucan; Laura Wingate; Sarah Buchanan; Nada Zmeter; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.